Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy |
| |
Authors: | Petrioli Roberto Paolelli Loretta Francini Edoardo Marsili Stefania Pascucci Alessandra Sciandivasci Angela de Rubertis Giovanni Barbanti Gabriele Manganelli Antonio Salvestrini Francesco Francini Guido |
| |
Institution: | Department of Human Pathology and Oncology, Medical Oncology Section, University of Siena, Policlinico Le Scotte, Viale Bracci 11, 53100 Siena, Italy. r.petrioli@ao-siena.toscana.it |
| |
Abstract: | The aim of this study was to evaluate the activity and toxicity of capecitabine as third-line treatment in patients with advanced renal cell carcinoma for whom immunotherapy had failed. Twenty-one patients with metastatic clear renal cell carcinoma were enrolled. Capecitabine was administered orally twice daily at a dosage of 2500 mg/m(2) for 14 days, followed by 7 days of rest. The median number of administered cycles was five (1-13). One patient (4.8%) achieved a remission after eight treatment cycles. Stable disease was observed in nine patients (42.8%), whereas 11 progressed (52.4%). The estimated median time to progression was 3.6 months (confidence interval: 1.4 to 5.2). The estimated median overall survival was 7.2 months (confidence interval: 4.6 to 8.8). The regimen was well tolerated and no unexpected toxic effects were observed. Capecitabine as third-line treatment showed a favourable toxicity profile, but exhibited low activity in patients with advanced renal cell carcinoma after failing immunotherapy. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|